Effects of Colchicine and Empagliflozin in Myocardial Dysfunctio
Phase 3
Completed
- Conditions
- Condition 1: Heart failure. Condition 2: ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction.Heart failureST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction
- Registration Number
- IRCT20111206008307N39
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 96
Inclusion Criteria
Heart Failure with Reduced Ejection Fraction
Aged 18 to 80 years
Consented patients
Exclusion Criteria
Pregnancy
Lactation
Liver failure
Kidney failure
Contraindications of colchicine or empagliflozin
Systolic blood pressure less than 100 or more than 180 mm Hg
Symptomatic hypotension
Autoinflammatory diseases
Malignancy
Diabetes mellitus
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method High-sensitivity C-reactive protein (hs-CRP). Timepoint: Before intervention and 1, and 3 months after intervention. Method of measurement: Laboratory test.;New York Heart Association (NYHA) Functional Classification. Timepoint: At baseline and 1, and 3 months after intervention. Method of measurement: Assessment by one cardiologist.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie colchicine and empagliflozin's effects on myocardial dysfunction in heart failure patients post-MI?
How does the combination of colchicine and empagliflozin compare to standard-of-care therapies for reducing ejection fraction in STEMI and NSTEMI patients?
Which biomarkers are associated with improved outcomes in IRCT20111206008307N39 for heart failure following myocardial infarction?
What are the potential adverse events of colchicine and empagliflozin in phase III trials for post-MI heart failure?
Are there alternative drug combinations or molecular targets for treating reduced ejection fraction in STEMI/NSTEMI patients compared to IRCT20111206008307N39?